Zacks: Brokerages Anticipate Denali Therapeutics Inc (NASDAQ:DNLI) Will Post Quarterly Sales of $18.69 Million

Analysts expect that Denali Therapeutics Inc (NASDAQ:DNLI) will announce sales of $18.69 million for the current quarter, Zacks reports. Four analysts have provided estimates for Denali Therapeutics’ earnings, with estimates ranging from $4.50 million to $51.89 million. Denali Therapeutics reported sales of $125.68 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 85.1%. The company is scheduled to report its next earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Denali Therapeutics will report full-year sales of $43.94 million for the current fiscal year, with estimates ranging from $26.51 million to $83.79 million. For the next year, analysts anticipate that the firm will post sales of $66.51 million, with estimates ranging from $16.61 million to $175.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Denali Therapeutics had a negative return on equity of 13.37% and a negative net margin of 44.73%. The business had revenue of $13.60 million for the quarter, compared to the consensus estimate of $10.86 million.

A number of research firms recently issued reports on DNLI. BTIG Research began coverage on Denali Therapeutics in a report on Friday, August 9th. They issued a “buy” rating and a $30.00 target price for the company. Morgan Stanley set a $32.00 target price on Denali Therapeutics and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research lowered Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. ValuEngine upgraded Denali Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Wedbush began coverage on Denali Therapeutics in a report on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 target price for the company. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Denali Therapeutics presently has an average rating of “Buy” and an average price target of $27.43.

DNLI stock traded up $0.11 during midday trading on Monday, hitting $15.25. 251,800 shares of the company’s stock were exchanged, compared to its average volume of 350,245. Denali Therapeutics has a 1-year low of $14.24 and a 1-year high of $28.86. The company has a current ratio of 10.59, a quick ratio of 10.59 and a debt-to-equity ratio of 0.16. The business has a 50-day simple moving average of $15.45 and a two-hundred day simple moving average of $18.83. The stock has a market capitalization of $1.44 billion, a PE ratio of -39.10 and a beta of 2.14.

In other Denali Therapeutics news, CEO Ryan J. Watts sold 8,581 shares of Denali Therapeutics stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.05, for a total transaction of $154,887.05. Following the completion of the sale, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at approximately $225,715.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total value of $136,200.00. 21.20% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. lifted its holdings in Denali Therapeutics by 18.3% during the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock worth $153,773,000 after buying an additional 1,145,003 shares during the last quarter. BlackRock Inc. lifted its holdings in Denali Therapeutics by 13.3% during the 2nd quarter. BlackRock Inc. now owns 5,154,097 shares of the company’s stock worth $106,999,000 after buying an additional 604,766 shares during the last quarter. Wasatch Advisors Inc. lifted its holdings in Denali Therapeutics by 21.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 996,147 shares of the company’s stock worth $20,680,000 after buying an additional 175,243 shares during the last quarter. Pictet Asset Management Ltd. purchased a new stake in Denali Therapeutics during the 2nd quarter worth about $15,349,000. Finally, Northern Trust Corp lifted its holdings in Denali Therapeutics by 1.0% during the 2nd quarter. Northern Trust Corp now owns 620,050 shares of the company’s stock worth $12,873,000 after buying an additional 6,063 shares during the last quarter. 74.87% of the stock is owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: What is the Difference Between Common Shares and Convertible Shares?

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.